| 3.38 -0.33 (-8.89%) | 07-08 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.28 |
1-year : | 4.92 |
| Resists | First : | 3.66 |
Second : | 4.21 |
| Pivot price | 3.57 |
|||
| Supports | First : | 2.76 |
Second : | 2.3 |
| MAs | MA(5) : | 3.75 |
MA(20) : | 3.62 |
| MA(100) : | 4.02 |
MA(250) : | 9.71 |
|
| MACD | MACD : | 0 |
Signal : | -0.1  |
| %K %D | K(14,3) : | 60.1 |
D(3) : | 70.2 |
| RSI | RSI(14): 44.5 |
|||
| 52-week | High : | 49.79 | Low : | 2.49 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ IXHL ] has closed above bottom band by 30.8%. Bollinger Bands are 57.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 26 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.64 - 3.67 | 3.67 - 3.69 |
| Low: | 3.27 - 3.29 | 3.29 - 3.31 |
| Close: | 3.35 - 3.38 | 3.38 - 3.41 |
Incannex Healthcare Limited is an Australian company dedicated to the research, development, and commercialization of medicinal cannabinoid products. The firm offers pharmaceutical-grade cannabinoid compounds under its proprietary Incannex brand. Its product pipeline includes several key assets: IHL-42X: This compound is currently undergoing Phase II clinical evaluation for the treatment of obstructive sleep apnea (OSA). Incannex partners with The Alfred Hospital and Novotech on this specific clinical program. IHL-216A: Designed to address traumatic brain injury (TBI). Furthermore, the Monash Trauma Group, part of Monash University's Department of Neuroscience, is conducting a study on IHL-216A's protective effects against sports-related concussions. IHL-675A: A unique formulation combining hydroxychloroquine and cannabidiol, developed for both the prevention and management of a range of inflammatory conditions. These include acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), asthma, bronchitis, rheumatoid arthritis, and inflammatory bowel diseases. Originally established in 2001 as Impression Healthcare Limited, the company officially changed its name to Incannex Healthcare Limited in June 2020. Incannex maintains its corporate headquarters in Sydney, Australia.
Tue, 07 Jul 2026
Incannex Healthcare(IXHL) Stock Options Chain | Quotes & News - Moomoo
Thu, 25 Jun 2026
Incannex's sleep apnea drug gets U.S. patent protection to 2040 - Stock Titan
Wed, 10 Jun 2026
Incannex (Nasdaq: IXHL) secures over A$11.1M in R&D tax incentives - Stock Titan
Tue, 09 Jun 2026
Sleep apnea and anxiety drug developer Incannex gets AGP buy rating at $18 - Stock Titan
Thu, 07 May 2026
Incannex Healthcare Recognized for Innovative Drug Development Solutions by MedTech Breakthrough - GlobeNewswire
Thu, 12 Mar 2026
Incannex $10M raise funds DReAMzz Phase 2 trial, preserves Phase 3 cash - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 12 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 12.3 (%) |
| Held by Institutions | 12 (%) |
| Shares Short | 770 (K) |
| Shares Short P.Month | 801 (K) |
| EPS | -16.63 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.5 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -32.2 % |
| Return on Equity (ttm) | -117.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.07 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -18 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -0.21 |
| PEG Ratio | 0 |
| Price to Book value | 0.61 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.29 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|